# Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis

> **NCT01020396** · PHASE1,PHASE2 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 579 (actual)

## Conditions studied

- Bacterial Vaginosis

## Interventions

- **DRUG:** Metronidazole
- **DRUG:** Metronidazole

## Key facts

- **NCT ID:** NCT01020396
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2003-03
- **Final completion:** 2003-03
- **Target enrollment:** 579 (ACTUAL)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01020396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01020396, "Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01020396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*